Speeding Up the Drug Review Process: Results Encouraging -- But Progress Slow.

Abstract

The Food and Drug Administration's efforts to speed drug review are encouraging. Since October 1, 1978, FDA has approved more drugs in less time than before despite an increased workload. The greatest reductions were made in approvals of important drugs (drugs that in FDA's judgment provide a therapeutic gain over any marketed drugs). However, these approvals represent only about 41 percent of those in process since October 1, 1978, and it is too early to tell whether the positive trend will continue. Reduction of approval time has not been consistent throughout all FDA divisions, and processing times should be further reduced. GAO is recommending actions that the Secretary of Health and Human Services could take to further reduce drug review time. (Author)

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 23, 1981
Accession Number
ADA111554

Entities

Organizations

  • United States Government Accountability Office

Tags

DTIC Thesaurus Topics

  • Biometrics
  • Chemistry
  • Clinical Trials
  • Commerce
  • Congress
  • Databases
  • Generic Drugs
  • Law
  • Natural Resources
  • Personnel Management
  • Pharmacology
  • Statistical Data
  • Task Forces
  • Test And Evaluation
  • Test Methods
  • United States
  • Workload

Fields of Study

  • Medicine

Readers

  • Child and Adolescent Substance Abuse Science in Autism Spectrum Disorders.
  • Clinical Trial Research.
  • Government Contracting/Procurement.